Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled time : 15:20 save search
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
Published: 2023-08-08 (Crawled : 15:20) - globenewswire.com
XBIT | $8.24 0.73% 3K
|
Health Technology
|
| O: 1.02%
H: 3.43%
C: 0.81%
trial therapy
Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference
Published: 2023-08-08 (Crawled : 15:20) - globenewswire.com
PSTV | News | $1.55 -4.91% 1.6K
|
Health Technology
|
| O: 1.53%
H: 8.3%
C: -0.38%
conference cancer trial therapeutics plus
Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion
Published: 2023-06-12 (Crawled : 15:20) - biospace.com/
SKYE | $13.1 -6.63% 12K
|
Transportation and Warehousing
|
| O: 0.0%
H: 11.92%
C: 5.3%
sbi-100 bioscience trial
Avidity Biosciences to Host Investor and Analyst Event Focused on AOC 1001 Topline Data from Phase 1/2 MARINA™ Trial on April 27, 2023
Published: 2023-04-13 (Crawled : 15:20) - biospace.com/
RNA | News M | $25.46 1.27% 84K
|
Health Technology
|
| O: 1.43%
H: 8.32%
C: 7.54%
topline trial
PathAI Announces Collaboration with GSK on NASH Phase 2b Clinical Trial
Published: 2023-03-30 (Crawled : 15:20) - biospace.com/
GSK | News | $40.82 -1.02% 230K
|
Health Technology
|
| O: 0.0%
H: 0.65%
C: 0.6%
collaboration trial nash
IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial
Published: 2023-02-13 (Crawled : 15:20) - biospace.com/
IMV | $0.8225 -2.74% 45K
|
Health Technology
| Email alert
Add to watchlist
trial positive results
Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting
Published: 2023-02-09 (Crawled : 15:20) - biospace.com/
IMMX | $2.22 -3.48% 2.7K
|
|
| O: -5.14%
H: 4.53%
C: -12.08%
nxc-201 expansion meeting t-cell trial response
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossExpects to Commence Phase 2a of CAReS During the First Quarter of 2023
Published: 2023-02-02 (Crawled : 15:20) - biospace.com/
AZNCF | News | $140.3 1.5K
|
Health Technology
|
| O: -2.3%
H: 2.11%
C: 1.78%
AZN | News | $70.905 0.08% 1.6M
|
Health Technology
|
| O: -0.31%
H: 0.05%
C: -0.33%
ARTL | News | $1.31 1K
|
Health Technology
|
| O: -1.27%
H: 1.67%
C: -0.96%
art27 treatment cares trial art27.13 phase 2b
Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
Published: 2023-01-25 (Crawled : 15:20) - biospace.com/
HOTH | $1.19 1.5K
|
Health Technology
|
| O: -1.76%
H: 2.79%
C: 2.79%
trial therapeutics therapy cancer growth
Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium
Published: 2023-01-19 (Crawled : 15:20) - biospace.com/
ALPMY | News | $9.49 480K
|
Manufacturing
|
| O: 0.2%
H: 0.0%
C: -0.46%
symposium trial asco positive
ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
Published: 2023-01-19 (Crawled : 14:20) - nantkwest.com
IBRX | $5.435 -1.0% 1.8M
|
Manufacturing
|
| O: -1.1%
H: 1.11%
C: 0.22%
fda trial presentation asco update cancer pancreatic type-b meeting
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
Published: 2023-01-06 (Crawled : 15:20) - biospace.com/
ATAI | $1.89 -4.06% 290K
|
Manufacturing
|
| O: -42.97%
H: 33.33%
C: 21.33%
pcn-101 sciences life trial depression phase 2b
ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors
Published: 2022-12-19 (Crawled : 15:20) - biospace.com/
IMMX | $2.22 -3.48% 2.7K
|
|
| O: -8.47%
H: 35.84%
C: 13.87%
imx-110 trial tumors
SELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
Published: 2022-12-08 (Crawled : 15:20) - biospace.com/
SLS | $1.585 -2.76% 310K
|
Health Technology
|
| O: -1.26%
H: 8.94%
C: 5.53%
life trial
Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint
Published: 2022-12-08 (Crawled : 15:20) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: -60.42%
H: 0.66%
C: -23.03%
hepatitis virus trial
Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in Australia
Published: 2022-12-02 (Crawled : 15:20) - biospace.com/
CYTO | $1.45 -8.23% 2.7M
|
Manufacturing
|
| O: -3.16%
H: 2.43%
C: 0.35%
australia trial therapeutics
AstraZeneca Trial in Anti-TIGIT Candidate Triggers $7.5M Payment to Compugent
Published: 2022-11-16 (Crawled : 15:20) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: 5.01%
H: 2.85%
C: -2.09%
candidate trial payment
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting
Published: 2022-10-14 (Crawled : 15:20) - biospace.com/
KZR | $0.826 45K
|
Health Technology
|
| O: 0.36%
H: 1.8%
C: 0.0%
sciences meeting lupus life kidney week trial results
LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Published: 2022-10-07 (Crawled : 15:20) - globenewswire.com
LVTX | $2.94 -1.34% 54K
|
|
| O: -0.58%
H: 7.9%
C: 4.06%
lava-051 immunotherapy meeting trial therapeutics cancer
Toppan's RemoPick System Uses Vuzix Smart Glasses to Support Remote Order Picking Trial for Homebound Seniors in Japan
Published: 2022-09-07 (Crawled : 15:20) - prnewswire.com
VUZI P | $1.335 1.91% 180K
|
Electronic Technology
|
| O: -0.13%
H: 5.23%
C: 2.95%
system japan smart glasses order trial
Gainers vs Losers
| 63% | 37% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
TROO | $1.57 44.04% 2.8M
|
Manufacturing
RILY | $30.87 42.13% 7.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
WHLM | $6.61 30.12% 400K
|
Commercial Services
MULN | News | $3.53 29.3% 4.8M
|
Information
RBBN 4 | $3.26 26.85% 1.2M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.